3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cisplatin
5
Carboplatin
5
Cyclophosphamide
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
pembrolizumab
3
Oxaliplatin
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Irinotecan
3
Gemcitabine
3
Fluorouracil
3
Docetaxel
3
Capecitabine
3
tislelizumab
2
fludarabine
2
Specimen Handling
2
Riluzole
2
Quality of Life
2
Psychiatric Rehabilitation
2
Oncolytic Virotherapy
2
Observation
2
Fluorodeoxyglucose F18
2
Fluorescein
2
Floxuridine
2
Filgrastim
2
Drug Therapy
2
Cetuximab
2
umbralisib
1
trifluridine tipiracil drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Interleukin-15
×
Sarcoma
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled